Eiger BioPharmaceuticals Q2 EPS $(0.47) Misses $(0.41) Estimate, Sales $4.64M Beat $4.57M Estimate
Portfolio Pulse from Benzinga Newsdesk
Eiger BioPharmaceuticals reported Q2 losses of $(0.47) per share, missing the analyst consensus estimate of $(0.41) by 14.63%. However, the company's quarterly sales of $4.64 million beat the estimate of $4.57 million by 1.60%. This represents a 13.49% increase over sales from the same period last year.
August 14, 2023 | 8:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eiger BioPharmaceuticals' Q2 earnings per share missed estimates, but sales exceeded expectations.
Eiger BioPharmaceuticals' Q2 earnings per share missed the analyst consensus, which could negatively impact investor sentiment. However, the company's sales exceeded estimates, which could offset some of the negative sentiment. The net impact on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100